influential [idcn]
Metabolic syndrome [dsyn]
Factor [ftcn]
Insulin Resistance [patf]
Efficacy [qlco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
atorvastatin [orch, phsu]
Patients [podg]
Metabolic syndrome [dsyn]
atherosclerotic [ftcn]
Coronary heart disease risk [inpr]
Background [cnce]
Metabolic syndrome [dsyn]
Insulin Resistance [patf]
Increasing [ftcn]
Prevalence [qnco]
Associated [qlco]
High Risk [qlco]
coronary heart disease [dsyn]
responses [orga]
Lipid [lipd]
Altered [ftcn]
Drug Therapy [topp]
This [euka]
Study [mnob]
Evaluated [ftcn]
effects [qlco]
Metabolic syndrome [dsyn]
Factor [ftcn]
Obesity, Abdominal [dsyn]
depleted [ftcn]
High Density Lipoprotein Cholesterol [bacs, lipd]
elevated triglycerides [fndg]
Blood Pressure [orgf]
Fasting [fndg]
Glucose [bacs, carb, phsu]
Insulin Resistance [patf]
EZETIMIBE/SIMVASTATIN [orch, phsu]
atorvastatin [orch, phsu]
Treatment Efficacy [qlco]
Patients [podg]
Metabolic syndrome [dsyn]
Methods [inpr]
This [euka]
Post [tmco]
Analysis [lbpr]
DOUBLE BLIND [resa]
randomized [resa]
Parallel Study [resa]
Group [idcn]
Subject [grup]
Hypercholesterolaemia [dsyn]
Metabolic syndrome [dsyn]
Moderately [qlco]
High [qlco]
Coronary heart disease risk [inpr]
Evaluated [ftcn]
effects [qlco]
baseline [bodm]
Metabolic syndrome [dsyn]
factors resistance [bacs, nnon]
Insulin [aapp, horm, phsu]
Percent [qnco]
Change [ftcn]
baseline [bodm]
Lipids [lipd]
Apolipoproteins [aapp, bacs]
High sensitivity [lbpr]
C-reactive protein [aapp, imft]
treatment [ftcn]
Usual [qlco]
Start [tmco]
Dose [qnco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
mg% [qnco]
atorvastatin [orch, phsu]
mg% [qnco]
mg% [qnco]
High dose [qnco]
mg% [qnco]
mg% [qnco]
Result [ftcn]
EZETIMIBE/SIMVASTATIN [orch, phsu]
atorvastatin [orch, phsu]
Efficacy [qlco]
Consistent [idcn]
Metabolic syndrome [dsyn]
Factor [ftcn]
Insulin Resistance [patf]
subgroups [virs]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Incremental [qnco]
Percent [qnco]
reductions [npop]
Non [ftcn]
High Density Lipoprotein Cholesterol [bacs, lipd]
Apolipoprotein B [aapp, bacs]
Total Cholesterol [lbpr]
Lipoprotein [aapp, bacs]
Ratios [qnco]
subgroups [virs]
larger [qnco]
Percent [qnco]
Increase [ftcn]
High Density Lipoprotein Cholesterol [bacs, lipd]
Apolipoprotein AI [aapp, bacs]
Non [ftcn]
Obese [dsyn]
High Density Lipoprotein Cholesterol [bacs, lipd]
mg dl [qnco]
subgroups [virs]
atorvastatin [orch, phsu]
Doses [qnco]
Compared [acty]
Triglycerides [bacs, lipd]
Very [qlco]
High sensitivity [lbpr]
C-reactive protein [aapp, imft]
Result [ftcn]
More [ftcn]
Variable [qlco]
Similar [qlco]
treatment [ftcn]
Group [idcn]
Conclusion [idcn]
magnitude [qnco]
Lipid [lipd]
Altered [ftcn]
effects [qlco]
Treatment Regimen [topp]
Similar [qlco]
Metabolic syndrome [dsyn]
Insulin Resistance [patf]
subgroups [virs]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Percent [qnco]
reductions [npop]
Lipid [lipd]
Fractions [qnco]
atorvastatin [orch, phsu]
Dose [qnco]
Comparison [acty]
Study [mnob]
Treatments [topp]
Well [qlco]
